SLS
SELLAS Life Sciences Group, Inc.
Biotechnology · Healthcare · United States
9.68
close · 2026-10-30
value
93
cheaper than peers93
quality
81
stronger fundamentals81
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | -1.5% | 98 |
| earnings yield, latest year | -2.6% | 95 |
| cash flow yield, 1 year ago | -1.8% | 93 |
| cash flow yield, 2 years ago | -1.9% | 91 |
| cash flow yield, 3 years ago | -1.4% | 88 |
| earnings yield, 1 year ago | -5.2% | 83 |
| earnings yield, 2 years ago | -13.8% | 68 |
| earnings yield, 3 years ago | -22.0% | 63 |
| price to book | 14.19× | 10 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.8% | 76 |
| return on equity | -43.6% | 71 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$17.7M |
| employees | 13 |
| first trade | 2008-03-12 |
| next earnings | not reported |
| fundamentals updated | 2026-08-03 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.25 | -0.50 | -1.34 | -2.13 | not reported |
| free cash flow | -$28.4M | -$35.4M | -$36.9M | -$28.3M | not reported |
| net income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | not reported |
| revenue | $0 | $0 | $0 | $1.0M | not reported |
| unusual items | not reported | not reported | $4,000 | -$9.7M | -$1.3M |